Biosimilars Council Commends Nixing ‘Arbitrary’ Interchangeability Designation

The Proposal Was Included In President Biden’s FY2025 Budget Request

The Biosimilars Council agreed with the US president’s proposal to remove the “unnecessary” designation for biosimilars, which strengthens the ongoing debate over the need for interchangeability.

Person putting files into a bin — • Source: Shutterstock

The Biosimilars Council, a division of US off-patent group the Association for Accessible Medicines, has applauded US president Joe Biden’s latest move to eliminate the biosimilar interchangeability designation in his fiscal year 2025 budget request.

Calling interchangeability an “arbitrary distinction”, the Biosimilars Council said that the US is the “only country in the world with this unnecessary designation for already-approved biosimilars.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Abiogen And mAbxience Join Forces In Italy

28 May 2025

• By Dave Wallace

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.

Teva Brings In European Trastuzumab With Prestige BioPharma Agreement

27 May 2025

• By Dean Rudge

Teva will now market biosimilar Herceptin in both the US and Europe, after penning an agreement with Singaporean firm Prestige BioPharma for its Tuznue rival to the monoclonal antibody to treat HER2-positive breast cancer and HER2-positive metastatic stomach cancer.

SteinCares Deal Leads Lupin’s Ranibizumab Into Latin America

27 May 2025

• By Dave Wallace

Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.

Hikma Gears Up To Enter US Biosimilars Market With Ustekinumab Nod

27 May 2025

• By Dave Wallace

Hikma is set to make its first launch into the competitive US biosimilars market after its Bio-Thera-partnered Stelara rival, Starjemza, was approved by the FDA.

Hikma Gears Up To Enter US Biosimilars Market With Ustekinumab Nod

27 May 2025

• By Dave Wallace

Hikma is set to make its first launch into the competitive US biosimilars market after its Bio-Thera-partnered Stelara rival, Starjemza, was approved by the FDA.